国际肿瘤学杂志

国际肿瘤学杂志››2013,Vol. 40››Issue (7): 503-506.

• 综述 •上一篇下一篇

贝伐珠单抗联合FOLFOX方案治疗转移性结直肠癌的研究进展

吴玉立, 吕超, 郑铎, 吴硕东

  1. 110004 沈阳市,中国医科大学附属盛京医院胆道血管外科
  • 出版日期:2013-07-08发布日期:2013-07-08
  • 通讯作者:吴硕东, E-mail：wushuodong@yahoo.cn E-mail:wushuodong@yahoo.cn

Research about Bevacizumab combined with FOLFOX protocol to treat metastasis colorectal cancer

WU Yu-Li, 吕Chao , ZHENG Duo, WU Shuo-Dong

  1. Department of Biliary Vascular Surgery, Sheng Jing Hospital of China Medical University, Shenyang 110004, China
  • Online:2013-07-08Published:2013-07-08
  • Contact:WU Shuo-dong E-mail:wushuodong@yahoo.cn

PDF

1713

摘要：结直肠癌目前常规化疗方案为FOLFOX方案(氟尿嘧啶、亚叶酸钙、奥沙利铂)，大量临床试验证明贝伐珠单抗联合FOLFOX方案治疗恶性肿瘤安全有效，但有高血压、神经毒性、胃肠道出血和穿孔等不良反应产生。对转移性结直肠癌患者应用此联合方案对整体生存时间、肿瘤应答率和生存质量进行的研究得出了不同的结论，其安全性和有效性仍需大样本RCT或Meta分析来进一步研究证明。

关键词:结直肠肿瘤,药物疗法,贝伐珠单抗

Abstract:The common therapy of colorectal cancer is FOLFOX scheme, which contains flurouracil, leucovorin and oxaliplatin. Numerous clinical trials have demonstrated that bevacizumab combined with FOLFOX scheme in cancer's therapy is safe and effective. But the adverse reactions including hypertension, neurovirulence, gastrointestinal bleeding and perforation are raised up. Scholars have carried out a series of studies for the overall survival times, tumor response rates and survival qualities for the patients with metastatic colorectal cancer which using the joint scheme, but they draw different conclusions The usefulness and safety of the joint scheme still need more RCT and meta-ananlysis to be proved.

Key words:Colorectal neoplasms,Drug therapy,Bevacizumab